Effects of 4-tertiary butylphenol on the tyrosinase activity in human melanocytes.
Vitiligo is a common dermatological disorder characterized by the development of complete pigment loss from focal lesions that tends to increase in size over time. The etiology of vitiligo, resulting in the disappearance of functional melanocytes from involved skin, is not clearly understood. As a consequence, no satisfactory therapy has been developed. A subtype of vitiligo, termed 'occupational' or 'contact' vitiligo, is increased in individuals who are exposed to materials containing phenolic derivatives, such as 4-tertiary butylphenol (4-TBP). Phenolic derivatives are structurally similar to tyrosine, the initial substrate of tyrosinase in the biochemical synthesis of melanin. Therefore, it has been proposed that phenolic derivatives compete with tyrosine for hydroxylation by tyrosinase and interfere with the completion of melanin synthesis and/or generate cytotoxic intermediates. Our results demonstrated that 4-TBP competitively inhibited both tyrosine hydroxylase and dihydroxyphenylalanine (DOPA) oxidase activities of tyrosinase, i.e., the first two catalytic steps in the biochemical conversion of tyrosine to melanin in cultured human melanocytes. This inhibition occurred at concentrations that did not influence the viability of melanocytes. The tyrosinase activity inhibited by 4-TBP was recovered after removing the treatment. 4-TBP did not affect the function of other enzymes, such as succinate-tetrazolium reductase, acid phosphatase and sulfatase. Since depigmentation occurred without a cytotoxic response after exposure of melanocytes to low concentration of 4-TBP, it is unclear whether the interaction between 4-TBP and tyrosinase leads to the destruction of the melanocytes in 'contact/occupational' vitiligo.
Yang
F
F
Department of Cell Biology, Neurobiology and Anatomy, University of Cincinnati College of Medicine, Ohio, USA.
Boissy
R E
RE
D000135:Acid Phosphatase / Q000187:drug effects / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D008247:Lysosomes / Q000201:enzymology; D008543:Melanins / Q000378:metabolism; D008544:Melanocytes / Q000187:drug effects / Q000201:enzymology*; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology; D014442:Monophenol Monooxygenase / Q000187:drug effects* / Q000378:metabolism*; D010636:Phenols / Q000494:pharmacology*; D013385:Succinate Dehydrogenase / Q000187:drug effects / Q000378:metabolism; D013429:Sulfatases / Q000187:drug effects / Q000378:metabolism; D014443:Tyrosine / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000187:drug effects / Q000378:metabolism
D004791:Enzyme Inhibitors; D008543:Melanins; D010636:Phenols; D014443:Tyrosine; C400976:succinic tetrazolium reductase; D014446:Tyrosine 3-Monooxygenase; D014442:Monophenol Monooxygenase; D013385:Succinate Dehydrogenase; D000135:Acid Phosphatase; D013429:Sulfatases; C006862:butylphen